Governments such as in Japan have been promoting the use of such devices.
A rising adoption of closed system drug transfer device for chemotherapy is driving the demand for the market producing such devices in the Asia Pacific, which is expected to reach $345.83m by 2027 from $75.23m in 2019 at a compound annual growth rate of 21.1%, according to ReportLinker.
Closed system drug-transfer devices (CSTD) provide protection against hazardous drugs or vapors during drug preparation and administration. These devices comprise components to filter dangerous vapors.
"Closed system drug transfer devices play a major role in providing protection to healthcare professionals who are in close proximity to antineoplastic drugs and other harmful medications," the report stated.
The technological advancements in handling of hazardous drugs and rising number of chemotherapeutic drug approvals are expected to fuel the growth of the market in Asia Pacific.
However, the lack of regulatory guidelines regarding the safety of health workers in emerging countries is holding back the growth of the market.
Still, government authorities have been emphasizing on the implementation of occupational health and safety standards, which offers lucrative opportunities for the growth of the market.
For instance, the use of closed systems for compounding chemotherapy medications has risen in Japan, owing to the support provided by the government with reimbursements for CSTD use.
Official guidelines from the Japanese Ministry of Health have also recommended the use of CSTDs in the preparation and administration of hazardous drugs.
In 2019, the push-to-turn systems segment accounted for the largest share of the market, attributed to the growing preference for push-to-turn mechanism due to its promise of superior protection and availability of the product.
Furthermore, the luer-lock systems segment is expected to register the highest growth rate in the closed systems drug transfer devices market by 2027.
Do you know more about this story? Contact us anonymously through this link.